CAS No. 294662-18-3 | LEVOFLOXACIN LACTATE
CAS No. 294662-18-3 | LEVOFLOXACIN LACTATE
CAS No. 294662-18-3 | LEVOFLOXACIN LACTATE
+
  • CAS No. 294662-18-3 | LEVOFLOXACIN LACTATE
  • CAS No. 294662-18-3 | LEVOFLOXACIN LACTATE
  • CAS No. 294662-18-3 | LEVOFLOXACIN LACTATE

CAS No. 294662-18-3 | LEVOFLOXACIN LACTATE

Name: LEVOFLOXACIN LACTATE CAS No. 294662-18-3 MF:C21H24FN3O6 MW:433.4301632 Purity:97% Package: 10g,25g,50g,100g,250g Worldwide Delivery

Categories:

Biochemicals

Product introduction

Introduction and application of  CAS No. 294662-18-3 | LEVOFLOXACIN LACTATE

 

Specification:

ITEMS

SPECIFICATION

CAS

294662-18-3

MF

C21H24FN3O6

MW

433.4301632

Storage condition

2-8°C

 

Indications:

Levofloxacin lactate is suitable for: 1. Urogenital system infections, including simple and complicated urinary tract infections, bacterial prostatitis, Neisseria gonorrhoeae urethritis or cervicitis (including those caused by enzyme-producing strains). 2. Respiratory tract infections, including acute bronchial infections and pulmonary infections caused by sensitive Gram-negative bacilli. 3. Gastrointestinal infection, caused by Shigella, Salmonella, enterotoxigenic Escherichia coli, Aeromonas hydrophila, Vibrio parahaemolyticus, etc. 4. Typhoid fever. 5. Bone and joint infections. 6. Skin and soft tissue infection. 7. Systemic infections such as sepsis.

 

Pharmacological effects:

Levofloxacin lactate has broad-spectrum antibacterial effect, and Chemicalbook has strong antibacterial effect. It is effective against most Enterobacteriaceae bacteria, such as Escherichia coli, Klebsiella spp., Proteus spp., Salmonella spp., Shigella spp. and Haemophilus influenzae. Gram-negative bacteria such as Legionella pneumophila and Neisseria gonorrhoeae have strong antibacterial activity. It also has antibacterial effects on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes, as well as Mycoplasma pneumoniae and Chlamydia pneumoniae, but its effect on anaerobic bacteria and enterococci is poor. This product is the L-body of ofloxacin, and its in vitro antibacterial activity is approximately twice that of ofloxacin. Its mechanism of action is by inhibiting the activity of bacterial DNA gyrase, preventing bacterial DNA synthesis and replication, leading to bacterial death.

 

Package and transportation :

Package: 10g,25g,50g,100g,250g

Transportation: by courier/ by air/ by sea

Key words:

Related Products

Related Products

Inquiry

SUBMIT